| 翻訳と辞書 |
| Bradanicline ： ウィキペディア英語版 |
Bradanicline
Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. 〔(TC-5619 Cognitive Dysfunction in Schizophrenia )〕 Phase I clinical trials were completed successfully, and it was in phase II trials.〔(Rethinking Schizophrenia )〕
In May 2011, AstraZeneca declined to exercise its right to license the compound.〔(Targacept retains full development rights for TC-5619 )〕 In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.〔(Targacept ends development of ADHD drug )〕 It was being studied for cognitive and memory enhancement.
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.〔http://adisinsight.springer.com/drugs/800026693〕 It was also discontinued for ADHD, and no longer seems to be being developed.〔
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Bradanicline」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|